Tenet Healthcare Q3 2026 earnings

THC · 2026-10-29 06:47 BMO ET · 8-K on SEC · 10-Q on SEC

Adjusted EBITDA and EPS grew strongly on higher revenues and improved margins, with a $147 million favorable impact from RCM transition activities.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$5,631M+6.5%+0.1%Ex. 99.1, Income Statement
EPS (GAAP)$12.41+221.5%+26.3%Ex. 99.1, Income Statement
EPS (adjusted)$6.64+79.5%+8.5%Ex. 99.1, Income Statement
Net income$1,000M+192.4%+21.1%Ex. 99.1, Income Statement
Adj. EBITDA$1,355M+23.3%+3.9%Ex. 99.1, Income Statement
Adj. EBITDA margin24.1%+3.3 pp+0.9 ppEx. 99.1, Income Statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Ambulatory Care$537M+9.1%39.6%Revenue +7.5%; same-facility rev +4.5%
Hospital Operations and Services$818M+34.8%60.4%Revenue +6.1%; includes $97M RCM timing benefit

Margins and costs

  • Gross margin N/A
  • Operating expenses $3,278M (+8.3% YoY)
  • One-offs in the quarter Revenue from contract termination: $646M (+100% YoY); RCM transition benefit: $147M favorable impact to Adj. EBITDA; Loss from early extinguishment of debt: $5M; Medicaid supplemental revenue: $32M favorable pre-tax impact
  • Effective tax rate 24% (24% federal + state estimate)
  • Non-GAAP bridge Adds back revenue from contract termination, impairment/restructuring costs, litigation costs, gains/losses on facility sales, and early debt extinguishment; excludes ordinary course litigation.

KPIs

MetricActualPrior quarterPrior yearChange
Adjusted EBITDA$1,355M$1,304M$1,099M+3.9% QoQ, +23.3% YoY
Adjusted diluted EPS$6.64$6.12$3.70+8.5% QoQ, +79.5% YoY
Net cash provided by operating activities$1,281M$585M$1,058M+119% QoQ, +21% YoY
Adjusted free cash flow$1,102M$444M$781M+148% QoQ, +41% YoY
Net debt to Adj. EBITDA2.11x2.33x2.25x-0.22 pp QoQ

Guidance

MetricGuidePrior guideChange
FY 2026 Adjusted EBITDA$5.05B to $5.20B$4.83B to $5.03B+$195M at midpoint
FY 2026 Adjusted Free Cash Flow$2.825B to $3.125B$2.725B to $3.025B+$100M at midpoint
FY 2026 Adjusted EBITDA margin22.9% to 23.2%22.1% to 22.4%+0.8 to 0.8 pp

What drove it

  • Revenue story Net operating revenues increased 6.5% YoY driven by higher adjusted admissions and pricing strength, partially offset by unfavorable payer mix; includes a $97M timing-related benefit from RCM transition activities.
  • EPS story Adjusted EPS grew 79.5% YoY driven by higher revenues, improved margins, and a $147M favorable impact from RCM transition activities.
  • One-off check RCM transition activities resulted in a $147M favorable net impact to Adjusted EBITDA in Q3 2026.

The good

  • Adjusted EBITDA margin expanded to 24.1% YoY (+3.3 pp)
  • Adjusted diluted EPS grew 79.5% YoY
  • Adjusted free cash flow grew 41% YoY to $1.102B
  • Net debt to Adj. EBITDA ratio improved to 2.11x

The bad

  • Payer mix headwinds due to lower exchange admissions
  • Ambulatory surgical cases down 1.5% YoY

The ugly

  • none

Open questions

  • Hospital segment same-hospital net patient service revenue per adjusted admission increased only 0.2% YoY
  • Hospital segment Adjusted EBITDA growth (34.8%) is significantly higher than Ambulatory Care (9.1%)
Full release

Earnings: THC — filed 2026-10-29

Tenet Healthcare Corp (THC) · Form 8-K, Item 2.02 · Filed · SEC filing

Tenet Reports Strong Third Quarter 2026 Results;

Raises 2026 Financial Outlook

• Net income available to common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share compared to $342 million, or $3.86 in third quarter 2025

• Adjusted diluted earnings per share¹ increased 79.5% to $6.64 in third quarter 2026 compared to $3.70 in third quarter 2025

• Third quarter 2026 Consolidated Adjusted EBITDA¹ increased 23.3% over third quarter 2025 to $1.355 billion; Third quarter 2026 Adjusted EBITDA margin was 24.1%

• Third quarter 2026 Ambulatory Care Adjusted EBITDA of $537 million increased 9.1% over third quarter 2025

• FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05 billion to $5.20 billion, a $195 million increase at the midpoint of the range; FY 2026 Adjusted Free Cash Flow outlook now expected to be in the range of $2.825 billion to $3.125 billion, a $100 million increase

DALLAS — October 29, 2026 — Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2026.

"Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management," said Saum Sutaria, M.D., Chairman and Chief Executive Officer of Tenet. "Our focus on patient-centered care, support for physician partners, technology-enabled growth and operating initiatives continue to deliver strong margins and free cash flow."

Page 1

Tenet’s results for third quarter 2026 versus third quarter 2025 are as follows:

• Net income available to the Company’s common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share, versus $342 million, or $3.86 per diluted share, in third quarter 2025.

• The Company had previously entered into certain agreements with CommonSpirit Health, related to Conifer Health Solutions, LLC ("Conifer"), whereby the parties agreed, in part, to the early conclusion and transition of our revenue cycle management services by December 31, 2026, (collectively, the "RCM Agreements").

• The transition of certain revenue cycle management services under the RCM Agreements occurred during the third quarter of 2026 and will be substantially complete by October 30, 2026. As a result of this revised timeline, during the three months ended September 30, 2026, we recognized cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million. These are timing-related adjustments and as such, do not impact total or full year 2026 expectations for revenue from contract termination or net operating revenues associated with the RCM Agreements.

• In addition, we recognized a benefit of approximately $50 million during the three months ended September 30, 2026 due to various transition activities, including efficiencies from the revised timeline described above. This, combined with the $97 million timing-related adjustment to net operating revenue mentioned above, resulted in a favorable net impact to Adjusted EBITDA of $147 million in the third quarter of 2026.

• Adjusted EBITDA¹ was $1.355 billion in third quarter 2026 compared to $1.099 billion in third quarter 2025, reflecting strong same facility revenue growth and disciplined expense management partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the $147 million favorable net impact described above.

Page 2

Balance Sheet and Cash Flows

• Net cash flows provided by operating activities for the nine months ended September 30, 2026 were $3.507 billion versus $2.809 billion for the nine months ended September 30, 2025.

• The Company generated adjusted free cash flow¹ of $2.524 billion for the nine months ended September 30, 2026 versus $2.247 billion for the nine months ended September 30, 2025.

• In the three months ended September 30, 2026, the Company repurchased 970,000 shares of common stock for $255 million. In the nine months ended September 30, 2026, the Company repurchased 7.99 million shares of common stock for $1.615 billion.

• In September 2026, the Company completed a private placement of $2.0 billion in aggregate principal amount of newly issued 6.250% senior notes maturing in 2034. The Company used the net proceeds from the sale of the notes, after payment of fees and expenses, to finance, together with cash on hand, the redemption of all $1.5 billion aggregate principal amount then outstanding of its 5.125% senior secured first lien notes due in 2027 and the partial redemption of $500 million outstanding of its 6.125% senior notes due in 2028.

• The Company’s ratio of net debt to Adjusted EBITDA¹ was 2.11x at September 30, 2026 compared to 2.33x at June 30, 2026 and 2.25x at December 31, 2025.

Page 3

Ambulatory Care (Ambulatory) Segment

Tenet’s Ambulatory business segment is comprised of the operations of United Surgical Partners International (USPI). As of September 30, 2026, USPI had interests in 535 ambulatory surgery centers (406 consolidated) and 25 surgical hospitals (seven consolidated) in 37 states.

• Third quarter 2026 net operating revenues increased 7.5% compared to third quarter 2025 driven by strong growth in consolidated same-facility net patient service revenues, acquisitions of facilities, and increased service lines.

• Surgical business same-facility system-wide net patient service revenues increased

4.5% in third quarter 2026 compared to third quarter 2025, with cases down 1.5% and net revenue per case up 6.1%. Net revenue per case growth was driven by higher acuity and favorable service mix.

• Third quarter 2026 Adjusted EBITDA increased 9.1% compared to third quarter 2025, due to strong growth in same-facility net patient service revenues, disciplined expense management, and contributions from acquisitions.

Page 4

Hospital Operations and Services (Hospital) Segment... (truncated)ment is primarily comprised of acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro-hospitals and physician practices. It also provides comprehensive end-to-end and focused point services, including hospital and physician revenue cycle management, patient communications and engagement support and value-based care solutions.

• Third quarter 2026 net operating revenues increased 6.1% from third quarter 2025 driven by an increase in adjusted admissions as well as continued pricing strength, partially offset by unfavorable payer mix due to lower exchange admissions. In addition, third quarter 2026 net operating revenues include a timing-related benefit of $97 million associated with the RCM Agreements as described on page 2.

• Same-hospital net patient service revenue per adjusted admission increased 0.2% year-over-year for third quarter 2026 primarily due to strength in commercial employer net patient revenues offset by unfavorable payer mix related to lower exchange admissions.

• Adjusted EBITDA in third quarter 2026 was $818 million compared to $607 million in third quarter 2025, reflecting strong growth in same-hospital revenue and disciplined expense management, partially offset by unfavorable payer mix due to lower exchange admissions. Results also include the net favorable impact of $147 million from transition activities described on page 2.

• In the third quarter of 2026, the Hospital segment recognized a $32 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years. Third quarter 2025 results included a $38 million favorable pre-tax impact for additional Medicaid supplemental revenues related to prior years.

Page 5

2026 Outlook¹

Tenet’s Outlook for full year 2026 (consolidated and by segment) follows. Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues.

Page 6

Management’s Webcast Discussion of Results

Tenet management will discuss the Company’s third quarter 2026 results in a webcast scheduled for 10:00 a.m. Eastern Time (9:00 a.m. Central Time) on October 29, 2026. Investors can access the webcast through the Company’s website at www.tenethealth.com/investors.

The slide presentation associated with the webcast referenced above, a copy of this earnings press release, and a related supplemental financial disclosures document will be available on the Company’s Investor Relations website on October 29, 2026.

Page 7

Cautionary Statement

Financial statements

Income Statement

Three Months Ended September 30, — Tenet’s results for third quarter 2026 versus third quarter 2025 are as follows: ($ in millions, except per share results)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net operating revenues75,6315,28916,62715,783
Net income available to Tenet common shareholders1,0003422,5281,036
Net income available to Tenet common shareholders per diluted share12.413.8630.0811.28
Adjusted EBITDA11,3551,0993,8213,383
Adjusted diluted earnings per share16.643.717.512.1

Income Statement

Three Months Ended September 30, — (Unaudited) (Dollars in millions, except per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – %Three Months Ended September 30, – 2025Three Months Ended September 30, – %Three Months Ended September 30, – Change
Net operating revenues5,631100.0%5,289100.0%6.5
Revenue from contract termination64611.5%100
Equity in earnings of unconsolidated affiliates641.1%641.2%
Operating expenses:
Salaries, wages and benefits2,17338.6%2,20441.7%-1.4
Supplies98317.5%93117.6%5.6
Other operating expenses, net1,18421.0%1,11921.2%5.8
Depreciation and amortization2173.8%2184.1%
Impairment and restructuring charges, and acquisition-related costs370.7%230.4%
Litigation and investigation costs (benefit)60.1%-11-0.2%
Net gains on sales, consolidation and deconsolidation of facilities-9-0.2%-20-0.4%
Operating income1,75031.1%88916.8%
Interest expense-203-206
Other non-operating income, net3729
Loss from early extinguishment of debt-5
Income before income taxes1,579712
Income tax expense-360-133
Net income1,219579
Less: Net income available to noncontrolling interests219237
Net income available to Tenet Healthcare Corporation common shareholders1,000342
Earnings per share available to Tenet Healthcare Corporation common shareholders:
Basic12.483.89
Diluted12.413.86
Weighted average shares and dilutive securities outstanding (in thousands):
Basic80,13487,951
Diluted80,60088,610

Income Statement

Nine Months Ended September 30, — (Unaudited) (Dollars in millions, except per share amounts)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – %Nine Months Ended September 30, – 2025Nine Months Ended September 30, – %Nine Months Ended September 30, – Change
Net operating revenues16,627100.0%15,783100.0%5.3
Revenue from contract termination1,4728.9%100
Equity in earnings of unconsolidated affiliates1801.1%1811.1%-0.6
Operating expenses:
Salaries, wages and benefits6,57839.6%6,48341.1%1.5
Supplies2,92817.6%2,77017.6%5.7
Other operating expenses, net3,48020.9%3,32821.0%4.6
Depreciation and amortization6614.0%6324.0%
Impairment and restructuring charges, and acquisition-related costs920.6%660.4%
Litigation and investigation costs360.2%340.2%
Net gains on sales, consolidation and deconsolidation of facilities-43-0.2%-4
Operating income4,54727.3%2,65516.8%
Interest expense-612-616
Other non-operating income, net12180
Loss from early extinguishment of debt-5
Income before income taxes4,0512,119
Income tax expense-881-396
Net income3,1701,723
Less: Net income available to noncontrolling interests642687
Net income available to Tenet Healthcare Corporation common shareholders2,5281,036

Income Statement

Three Months Ended — (Unaudited) (Dollars in millions, except per share amounts)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net income available to Tenet Healthcare Corporation common shareholders1,0003422,5281,036
Less:
Revenue from contract termination6461,472
Impairment and restructuring charges, and acquisition-related costs-37-23-92-66
Litigation and investigation benefit (costs)-611-36-34
Net gains on sales, consolidation and deconsolidation of facilities920434
Loss from early extinguishment of debt-5-5
Tax and noncontrolling interests impact of above items-1426-32521
Adjusted net income available to common shareholders5353281,4711,111
Diluted earnings per share12.413.8630.0811.28
Revenue from contract termination8.0117.51
Impairment and restructuring charges, and acquisition-related costs-0.46-0.26-1.09-0.72
Litigation and investigation benefit (costs)-0.070.12-0.43-0.37
Net gains on sales, consolidation and deconsolidation of facilities0.110.230.510.04
Loss from early extinguishment of debt-0.06-0.06
Tax and noncontrolling interests impact of above items-1.760.07-3.860.23
Adjusted diluted earnings per share6.643.717.512.1
Weighted average basic shares outstanding (in thousands)80,13487,95183,48691,109
Weighted average dilutive shares outstanding (in thousands)80,60088,61084,05391,805

Income Statement

Three Months Ended — (Unaudited) (in millions)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net income available to Tenet Healthcare Corporation common shareholders1,0003422,5281,036
Less:
Net income available to noncontrolling interests-219-237-642-687
Net income1,2195793,1701,723
Income tax expense-360-133-881-396
Loss from early extinguishment of debt-5-5
Other non-operating income, net372912180
Interest expense-203-206-612-616
Operating income1,7508894,5472,655
Revenue from contract termination6461,472
Depreciation and amortization-217-218-661-632
Impairment and restructuring charges, and acquisition-related costs-37-23-92-66
Litigation and investigation benefit (costs)-611-36-34
Net gains on sales, consolidation and deconsolidation of facilities920434
Adjusted EBITDA1,3551,0993,8213,383
Net operating revenues5,6315,28916,62715,783
Net income available to Tenet Healthcare Corporation common shareholders as a % of net operating revenues17.86.515.26.6
Adjusted EBITDA as a % of net operating revenues (Adjusted EBITDA margin)24.120.82321.4

Income Statement

(Unaudited) (Dollars in millions, except per share amounts)

Low – FY 2026High
Net income available to Tenet Healthcare Corporation common shareholders2,9733,078
Less:
Revenue from contract termination1,6501,650
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)-180-150
Net gains on sales, consolidation and deconsolidation of facilities(2)4343
Loss from early extinguishment of debt(2)-5-5
Tax and noncontrolling interests impact of above items-365-370
Adjusted net income available to common shareholders1,8301,910
Diluted earnings per share35.8237.08
Revenue from contract termination19.8819.88
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements-2.17-1.81
Net gains on sales, consolidation and deconsolidation of facilities0.520.52
Loss from early extinguishment of debt-0.06-0.06
Tax and noncontrolling interests impact of above items-4.4-4.46
Adjusted diluted earnings per share22.0523.01
Weighted average dilutive shares outstanding (in thousands)83,00083,000

Income Statement

(Unaudited) (in millions)

Low – FY 2026High
Net income available to Tenet Healthcare Corporation common shareholders2,9733,078
Less:
Net income available to noncontrolling interests-910-960
Income tax expense-1,135-1,170
Interest expense-825-815
Loss from early extinguishment of debt(2)-5-5
Other non-operating income, net150200
Net gains on sales, consolidation and deconsolidation of facilities(2)4343
Impairment and restructuring charges, acquisition-related costs, and litigation costs and settlements(1)-180-150
Depreciation and amortization-865-915
Revenue from contract termination1,6501,650
Adjusted EBITDA5,0505,200
Net income available to Tenet Healthcare Corporation common shareholders2,9733,078
Net operating revenues22,05022,450

Balance Sheet

September 30, 2026 — (Unaudited) (in millions)

September 30, 2026December 31, 2025
Cash and cash equivalents2,6742,883
Accounts receivable2,5952,565
Inventories of supplies, at cost340348
Assets held for sale6262
Other current assets2,7571,991
Total current assets8,4287,849
Investments and other assets3,9582,883
Deferred income taxes4984
Property and equipment, at cost, less accumulated depreciation and amortization6,2906,315
Goodwill11,64111,198
Other intangible assets, at cost, less accumulated amortization1,2261,348
Total assets31,59229,677
Current liabilities:
Current portion of long-term debt16479
Accounts payable1,3871,360
Accrued compensation and benefits873858
Professional and general liability reserves317276
Accrued interest payable21381
Income tax payable22
Other current liabilities2,3421,809
Total current liabilities5,3184,463
Long-term debt, net of current portion13,07913,092
Professional and general liability reserves979951
Defined benefit plan obligations238245
Deferred income taxes529240
Other long-term liabilities1,8551,713
Total liabilities21,99820,704
Commitments and contingencies
Redeemable noncontrolling interests in equity of consolidated subsidiaries2,1792,956
Shareholders’ equity:
Common stock88
Additional paid-in capital5,2364,914
Accumulated other comprehensive loss-178-181
Retained earnings6,9434,415
Common stock in treasury, at cost-6,565-4,936
Total shareholders’ equity5,4444,220
Noncontrolling interests1,9711,797
Total equity7,4156,017
Total liabilities and equity31,59229,677

Cash Flow

Description — Third Quarter Earnings Release

Page
Consolidated Statements of Operations12
Consolidated Balance Sheets14
Consolidated Statements of Cash Flows15
Segment Reporting16
Table #1 – Reconciliations of Net Income to Adjusted Net Income17
Table #2 – Reconciliations of Net Income to Adjusted EBITDA18
Table #3 – Reconciliations of Net Cash Provided by Operating Activities to Free Cash Flow and Adjusted Free Cash Flow19
Table #4 – Reconciliations of Outlook Net Income to Outlook Adjusted Net Income20
Table #5 – Reconciliations of Outlook Net Income to Outlook Adjusted EBITDA21
Table #6 – Reconciliations of Outlook Net Cash Provided by Operating Activities to Outlook Free Cash Flow and Outlook Adjusted Free Cash Flow22

Cash Flow

Nine Months Ended — (Unaudited) (in millions)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net income3,1701,723
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization661632
Deferred income tax expense32451
Stock-based compensation expense10479
Impairment and restructuring charges, and acquisition-related costs9266
Litigation and investigation costs3634
Net gains on sales, consolidation and deconsolidation of facilities-43-4
Loss from early extinguishment of debt5
Equity in earnings of unconsolidated affiliates, net of distributions received-11-13
Amortization of debt discount and debt issuance costs1618
Other items, net-11-5
Changes in cash from operating assets and liabilities:
Accounts receivable-1168
Inventories and other current assets211-58
Income taxes6315
Accounts payable, accrued expenses and other current liabilities-1,042237
Other long-term liabilities4650
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements-103-84
Net cash provided by operating activities3,5072,809
Cash flows from investing activities:
Purchases of property and equipment-546-646
Purchases of businesses or joint venture interests, net of cash acquired-201-266
Proceeds from sales of facilities and other assets1118

Cash Flow

(Unaudited) (in millions)

Q3 – 2026YTD
Net cash provided by operating activities1,2813,507
Purchases of property and equipment-198-546
Free cash flow1,0832,961
Net cash used in investing activities-298-818
Net cash used in financing activities-479-2,898
Net cash provided by operating activities1,2813,507
Less:
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements-19-103
Cash received for contract termination540
Adjusted net cash provided by operating activities1,3003,070
Purchases of property and equipment-198-546
Adjusted free cash flow1,1022,524

Cash Flow

(Unaudited) (in millions)

Q3 – 2025YTD – 2025
Net cash provided by operating activities1,0582,809
Purchases of property and equipment-280-646
Free cash flow7782,163
Net cash used in investing activities-385-886
Net cash used in financing activities-323-1,967
Net cash provided by operating activities1,0582,809
Less:
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements-3-84
Adjusted net cash provided by operating activities1,0612,893
Purchases of property and equipment-280-646
Adjusted free cash flow7812,247

Cash Flow

(Unaudited) (in millions)

Low – FY 2026High – FY 2026
Net cash provided by operating activities3,8854,315
Purchases of property and equipment-700-800
Free cash flow3,1853,515
Net cash provided by operating activities3,8854,315
Less:
Payments for restructuring charges, acquisition-related costs and litigation costs and settlements(1)-180-150
Cash received for contract termination540540
Adjusted net cash provided by operating activities3,5253,925
Purchases of property and equipment-700-800
Adjusted free cash flow(2)2,8253,125

Income Statement ($ in millions, except per share amounts)

FY 2026 Outlook
Net operating revenues7$22,050 to $22,450
Net income available to Tenet common shareholders$2,973 to $3,078
Adjusted EBITDA$5,050 to $5,200
Adjusted EBITDA margin22.9% to 23.2%
Diluted income per common share$35.82 to $37.08
Adjusted net income$1,830 to $1,910
Adjusted diluted earnings per share$22.05 to $23.01
Equity in earnings of unconsolidated affiliates$265 to $275
Depreciation and amortization$865 to $915
Interest expense$815 to $825
Income tax expense5$1,135 to $1,170
Net income available to NCI$910 to $960
Weighted average diluted common shares~83 million
Net cash provided by operating activities$3,885 to $4,315
Adjusted net cash provided by operating activities$3,525 to $3,925
Capital expenditures$700 to $800
Free cash flow$3,185 to $3,515
Adjusted free cash flow$2,825 to $3,125
NCI cash distributions$900 to $970

This release contains “forward-looking statements” - that is, statements that relate to future, not past, events. In this context, forward-looking statements often address the Company’s expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause the Company’s actual results to be materially different than those expressed in the Company’s forward-looking statements include, but are not limited to the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2025 and other filings with the Securities and Exchange Commission.

Footnotes

1.

Tables and discussions throughout this earnings release include certain financial measures, including those related to our full year 2026 Outlook, that are not in accordance with accounting principles generally accepted in the United States of America (GAAP). Reconciliations of GAAP measures to the Adjusted (non-GAAP) measures used are detailed in Tables #1-6 included at the end of this earnings release. Management’s reasoning for the use of these non-GAAP measures and descriptions of the various non-GAAP measures are included in the Non-GAAP Financial Measures section of this earnings release.

2.

Same-facility system-wide revenues and statistical information include the results of the facilities in which the Ambulatory segment has an investment that are not consolidated by Tenet. To help analyze the segment’s results of operations, management uses system-wide measures, which include revenues and cases of both consolidated and unconsolidated facilities.

3.

For 2026, same-hospital revenues and statistical data include those for hospitals and hospital-affiliated outpatient centers operated by the Company’s Hospital segment continuously from January 1, 2025 through September 30, 2026. Amounts associated with physician practices are excluded.

4.

Adjusted admissions represent actual patient admissions adjusted to include outpatient services provided by facilities in our Hospital segment by multiplying actual patient admissions by the sum of gross inpatient revenues and outpatient revenues, then dividing that result by gross inpatient revenues.

5.

Income tax expense is calculated by multiplying 24% (the federal corporate tax rate of 21% plus an estimate of state taxes) by the sum of: pretax income less NCI expense plus permanent differences, and non-deductible interest expense.

6.

Change versus prior year is presented on a same-facility system-wide basis for USPI Ambulatory surgical cases and on a same-hospital basis for hospital statistics.

7.

Contract termination revenue recognized from the early conclusion of the RCM Agreements is not included in net operating revenues.

Page 8

About Tenet Healthcare... (truncated)re and specialty hospitals, other outpatient facilities, a network of leading employed physicians and a global business center in Manila, Philippines. Our Conifer Health Solutions subsidiary provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Across the Tenet enterprise, we are united by our mission to deliver quality, compassionate care in the communities we serve. For more information, please visit www.tenethealth.com.

Contact Information

Page 9

Non-GAAP Financial Measures

The Company believes the non-GAAP measures described below are useful to investors and analysts because they present additional information on the Company’s financial performance. Investors, analysts, Company management and the Company’s Board of Directors utilize these non-GAAP measures, in addition to GAAP measures, to track the Company’s financial and operating performance and compare the Company’s performance to its peer companies, which use similar non-GAAP financial measures in their presentations and earnings releases. The Human Resources Committee of the Company’s Board of Directors also uses certain of these measures to evaluate management’s performance for the purpose of determining incentive compensation. Additional information regarding the purpose and utility of specific non-GAAP measures used in this release is set forth below.

• Adjusted EBITDA is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) the cumulative effect of changes in accounting principles, (2) net loss attributable (income available) to noncontrolling interests, (3) income (loss) from discontinued operations, net of tax, (4) income tax benefit (expense), (5) gain (loss) from early extinguishment of debt, (6) other non-operating income (expense), net, (7) interest expense, (8) litigation and investigation benefit (costs), net of insurance recoveries, (9) net gains (losses) on sales, consolidation and deconsolidation of facilities, (10) impairment and restructuring charges and acquisition-related costs, (11) depreciation and amortization, (12) income (loss) from divested and closed businesses (i.e., health plan businesses) and (13) revenue from contract termination. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

• Adjusted diluted earnings (loss) per share is defined by the Company as Adjusted net income available (loss attributable) to Tenet common shareholders, divided by the weighted average diluted shares outstanding in the reporting period.

• Adjusted net income available (loss attributable) to Tenet common shareholders is defined by the Company as net income available (loss attributable) to Tenet common shareholders before (1) income (loss) from discontinued operations, net of tax, (2) gain (loss) from early extinguishment of debt, (3) litigation and investigation benefit (costs), net of insurance recoveries, (4) net gains (losses) on sales, consolidation and deconsolidation of facilities, (5) impairment and restructuring charges and acquisition-related costs, (6) income (loss) from divested and closed businesses (i.e., health plan businesses), (7) revenue from contract termination and (8) the associated impact of these items on taxes and noncontrolling interests. Revenue from contract termination represents the present value of the $1.9 billion of consideration related to the early termination of Conifer’s revenue cycle services agreement with CommonSpirit (as further described in the Company’s Form 8-K dated February 2, 2026), net of amortization of an associated contract asset. Litigation and investigation benefit (costs) excluded do not include ordinary course of business malpractice and other litigation and related expenses.

• Free Cash Flow is defined by the Company as (1) net cash provided by (used in) operating activities, less (2) purchases of property and equipment.

• Adjusted Free Cash Flow is defined by the Company as (1) Adjusted net cash provided by (used in) operating activities, less (2) purchases of property and equipment.

• Adjusted net cash provided by (used in) operating activities is defined by the Company as cash provided by (used in) operating activities prior to (1) payments for restructuring charges, acquisition-related costs and litigation costs and settlements, (2) net cash provided by (used in) operating activities from discontinued operations and (3) cash received for contract termination defined above.

The Company believes that Adjusted EBITDA is a useful measure, in part, because certain investors and analysts use both historical and projected Adjusted EBITDA, in addition to other GAAP and non-GAAP measures, as factors in determining the estimated fair value of shares of the Company’s common stock. Company management also regularly reviews the Adjusted EBITDA performance for each operating segment. The Company does not use Adjusted EBITDA to measure liquidity, but instead to measure operating performance.

The Company uses, and believes investors use, Free Cash Flow and Adjusted Free Cash Flow as supplemental non-GAAP measures to analyze cash flows generated from the Company’s operations. The Company believes these measures are useful to investors in evaluating its ability to fund distributions paid to noncontrolling interests or for acquisitions, purchasing equity interests in joint ventures or repaying debt.... (truncated)exclude many items that are included in the Company’s financial statements, they do not provide a complete measure of the Company’s operating performance. For example, the Company’s definitions of Free Cash Flow and Adjusted Free Cash Flow do not include other important uses of cash including (1) cash used to purchase businesses or joint venture interests, or (2) any items that are classified as Cash Flows from Financing Activities on the Company’s Consolidated Statement of Cash Flows, including items such as (i) cash used to repay borrowings, or (ii) distributions paid to noncontrolling interests. Accordingly, investors are encouraged to use GAAP measures when evaluating the Company’s financial performance.

See corresponding reconciliations of the non-GAAP financial measures referred to above to the most comparable GAAP financial measures in Tables #1 - 6 below.

Page 10

Tenet Healthcare Corporation

Financial Statements and Reconciliations

Third Quarter Earnings Release

Table of Contents

Page 11

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.